Risankizumab for the Treatment of Palmoplantar Pustular Psoriasis: A Report of Two Cases

Citation: Gargiulo L, Vignoli CA, Pavia G, Narcisi A, Costanzo A, Perugini C. Risankizumab for the Treatment of Palmoplantar Pustular Psoriasis: A Report of Two Cases. Dermatol Pract Concept. 2023;13(2):e2023097. DOI: https://doi.org/10.5826/dpc.1302a97

Accepted: July 27, 2023; Published: April 2023

Copyright: ©2023 Gargiulo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (BY-NC-4.0), https://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.

Funding: None.

Competing interests: Antonio Costanzo has been a consultant and/or speaker for Abb-Vie, Almirall, Amgen, Janssen, Leo Pharma, Eli Lilly, Galderma, Boehringer, Novartis, Pfizer, Sandoz, and UCB. Alessandra Narcisi has been a consultant and/or speaker for Abb-Vie, Almirall, Amgen, Janssen, Leo Pharma, Eli Lilly, Boehringer, Novartis, Pfizer and UCB. Luigi Gargiulo, Carlo Alberto Vignoli, Giulia Pavia and Chiara Perugini have nothing to disclose.

Authorship: All authors have contributed significantly to this publication.

Corresponding author: Dr. Carlo Alberto Vignoli, MD, Dermatology Unit, Department of Biomedical Sciences,  IRCCS Humanitas Research Hospital, Humanitas University, Rozzano (MI), Itlay.  Tel: +39 0282244050 Email: c.alberto.vignoli@gmail.com

Abstract

Keywords : psoriasis, palmoplantar pustular psoriasis, risankizumab, biologics, anti-IL-23

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

References

1. Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792-1799. DOI:10.1111/jdv.14386. PMID: 28585342. 2. Uppala R, Tsoi LC, Harms PW, et al. "Autoinflammatory psoriasis"-genetics and biology of pustular psoriasis. Cell Mol Immunol. 2021;18(2):307-317. DOI:10.1038/s41423-020-0519-3. PMID: 32814870. PMCID: PMC8027616. 3. Wang WM, Jin HZ. Biologics in the treatment of pustular psoriasis. Expert Opin Drug Saf. 2020;19(8):969-980. DOI:10.1080/14740338.2020.1785427. PMID: 32615817. 4. Mrowietz U, Bachelez H, Burden AD, et al. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study. J Am Acad Dermatol. 2019;80(5):1344-1352. DOI:10.1016/j.jaad.2019.01.066. PMID: 30716404. 5. Borroni RG, Malagoli P, Gargiulo L, et al. Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study. Acta Derm Venereol. 2021;101(11):adv00605. DOI:10.2340/actadv.v101.283. PMID: 34596230. PMCID: PMC9455321. 6. Gargiulo L, Pavia G, Valenti M, et al. Safety of Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Viral Hepatitis: A Monocentric Retrospective Study. Dermatol Ther (Heidelb). 2022;12(5):1263-1270. DOI:10.1007/s13555-022-00726-w. PMID: 35460018. PMCID: PMC9110615.